Recent secondary market transactions have pushed Neuralink’s implied valuation into the $42–60 billion range, up sharply from its $9–9.7 billion Series E post-money in mid-2025, as private equity demand reflects ongoing clinical momentum. Patient enrollment has risen to 26 worldwide, with trials active in the U.S., Canada, UK, and UAE, while participants logged over 50,000 hours of neural data, enabling a new 11.32 bits-per-second cursor-control record and reduced calibration needs. These technical gains, alongside expanded programs targeting speech and vision restoration, underpin trader sentiment ahead of the late-October resolution. No near-term IPO or primary funding round is expected, leaving secondary pricing as the key observable benchmark.